EUVIMEDEUVIMED entdecken
Crossref

The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis

Andrea Marchetti, Veronica Mollica, Andrea Farolfi, Gianfilippo Bianciardi, Matteo Rosellini, Elisa Tassinari, Linda Danielli, Lorenzo Bianchi, Riccardo Schiavina, Stefano Fanti, Francesco Massari

Clinical Genitourinary Cancer · 2025

DOI: 10.1016/j.clgc.2025.102406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Genitourinary Cancer, 2025. Verfasst von Andrea Marchetti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: In metastatic hormone-sensitive prostate cancer (mHSPC), to evaluate therapy response is currently used conventional imaging and PSA levels. Positron emission tomography with 68Gallium Prostate-specific membrane antigen (68Ga-PSMA-PET/CT) could be useful, although it is not recommended by international guidelines. Its prognostic utility has been already investigated in several works in the castration-resistant setting, but no sufficient efforts have been made to better define it in mHSPC. METHODS: Retrospective monocentric study to preliminary explore the value of 68Ga-PSMA-PET/CT in this setting. We enrolled metastatic patients at the baseline 68Ga-PSMA-PET/CT, treated with androgen deprivation therapy plus docetaxel or androgen receptor signaling inhibitors (ARSI) or both as first-line. KEY FINDINGS AND LIMITATIONS: The survival analysis indicated that a Major SUVmax exceeding the cut-off (P = .037) and a SUVmean above the cut-off (P = .025) were linked to improved progression-free survival (PFS) as compared to values ≤ cut-off. While several parameters were associated with undetectable PSA levels at any point after the initiation of first-line therapy, only low-volume disease (HR 7.64, P .002), MTV ≤ cut-off 3-months PSA (HR 5.36, P = .012) and SUVmean ≤ cut-off 3-months PSA (HR 38.6, P < .001) were associated with a higher probability of reaching an undetectable value of PSA in the multivariate analysis. LIMITATIONS: retrospective nature, short follow-up time and lack of comparison with conventional imaging. CONCLUSION AND CLINICAL IMPLICATIONS: Lower values of 68Ga-PSMA-PET/CT derived-parameters at baseline are negative prognostic factor, in view of the correlation with lower PFS. This study could help oncologists in the management of mHSPC patients, although further investigations are needed to better understand the prognostic and predictive 68Ga-PSMA-PET/CT role in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsHumansMaleRetrospective StudiesAgedGallium RadioisotopesPrognosisGallium IsotopesMiddle AgedAndrogen AntagonistsAged, 80 and overDocetaxelRadiopharmaceuticalsProstate-Specific AntigenOligopeptidesProgression-Free Survival

Stichwörter der Autor:innen

PET/CTPSMAPrognostic factorUndetectable PSAmHSPC

Substanzen

Gallium RadioisotopesGallium Isotopesgallium 68 PSMA-11Androgen AntagonistsDocetaxelRadiopharmaceuticalsProstate-Specific AntigenOligopeptides

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Università degli studi di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Electronic address: francesco.massari@aos…

Zitieren

APA

Marchetti, A., Mollica, V., Farolfi, A., Bianciardi, G., Rosellini, M., Tassinari, E., Danielli, L., Bianchi, L., Schiavina, R., Fanti, S., & Massari, F. (2025). The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2025.102406

Vancouver

Marchetti A, Mollica V, Farolfi A, Bianciardi G, Rosellini M, Tassinari E, et al. The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis. Clinical Genitourinary Cancer. 2025. doi:10.1016/j.clgc.2025.102406

BibTeX
@article{Marchetti2025,
  author = {Marchetti, Andrea and Mollica, Veronica and Farolfi, Andrea and Bianciardi, Gianfilippo and Rosellini, Matteo and Tassinari, Elisa and Danielli, Linda and Bianchi, Lorenzo and Schiavina, Riccardo and Fanti, Stefano and Massari, Francesco},
  title = {The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis},
  journal = {Clinical Genitourinary Cancer},
  year = {2025},
  doi = {10.1016/j.clgc.2025.102406}
}
Kostenlos starten →